Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award
Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards which recognizes Australia’s fastest-growing technology companies and the founders, innovators and leaders shaping the future of the sector. The award recognizes Mesoblast’s successful evolution to a commercial-stage biotechnology company following its U.S. launch of Ryoncil® (remestemcel-L-rknd), the first mesenchymal stromal cell therapy approved by the U.S. Food and Drug Administration (FDA).1 "We ar